The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: CDK5 (Cyclin-Dependent Kinase 5) - Human Gene Q00535

Gene Identity and Basic Characterization

CDK5 (Cyclin-Dependent Kinase 5, UniProt Q00535) is a proline-directed serine/threonine protein kinase in humans belonging to the CMGC Ser/Thr protein kinase superfamily (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, pao2021threedecadesof pages 1-3). Unlike other cyclin-dependent kinases, CDK5 is an atypical family member that does not directly participate in cell cycle regulation and instead plays critical roles in post-mitotic neurons (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, allnutt2020physiologicalandpathological pages 1-2). The protein exhibits approximately 60% sequence homology with CDC2/CDK1 but possesses distinct regulatory mechanisms and biological functions (pao2021threedecadesof pages 1-3).

Primary Enzymatic Function and Substrate Specificity

CDK5 functions as a proline-directed serine/threonine kinase that catalyzes the phosphorylation of substrates at SP/TP motifs, with a preference for basic residues flanking the phosphorylation site (nikhil2023cdk5anoncogene pages 1-2). The enzyme requires activation by non-cyclin regulatory proteins, specifically p35 (CDK5R1) or p39 (CDK5R2), rather than the canonical cyclins used by other CDK family members (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, pao2021threedecadesof pages 1-3, allnutt2020physiologicalandpathological pages 1-2).

CDK5 is an atypical cyclin-dependent kinase: unlike classical CDKs, it is not activated by canonical cyclins and instead requires the non-cyclin regulatory subunits p35 or p39 for kinase activation. These activators are structurally distinct from cyclins and are especially important in post-mitotic neurons (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, pao2021threedecadesof pages 1-3, gao2021posttranslationalmodificationsof pages 1-3)

Under physiological conditions, p35 and p39 are myristoylated at Gly2, which targets them to membrane fractions and recruits active CDK5 complexes to the cell membrane. Active CDK5/p35 can also be present in the cytoplasm, but membrane association is a key feature of normal spatial regulation (pao2021threedecadesof pages 1-3, pao2021threedecadesof pages 3-4, gao2021posttranslationalmodificationsof pages 1-3)

Under pathological calcium-dependent conditions, calpain cleaves p35 to p25 and p39 to p29. These truncated activators lose the N-terminal myristoylated/membrane-targeting region and degradation signal, giving them longer half-lives and allowing CDK5 complexes to relocalize from the membrane to the cytoplasm and nucleus (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, allnutt2020physiologicalandpathological pages 1-2, gao2021posttranslationalmodificationsof pages 1-3)

The resulting CDK5/p25 or CDK5/p29 complexes are hyperactive and mislocalized, which broadens substrate access and promotes aberrant phosphorylation of physiological and non-physiological targets. This mechanism is linked to neurotoxicity, tau hyperphosphorylation, mitochondrial dysfunction, and other pathological signaling outputs (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 3-4, allnutt2020physiologicalandpathological pages 1-2, pao2021threedecadesof pages 4-5)

CDK5 activity is also tuned by post-translational modifications. Phosphorylation at Thr14 is inhibitory, phosphorylation at Tyr15 is generally stimulatory but context-dependent, and phosphorylation at Ser159 promotes p35-dependent activation. S-nitrosylation at Cys83 within the ATP-binding pocket suppresses kinase activity, whereas acetylation at Lys33 impairs ATP binding and reduces catalytic activity (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 3-4, gao2021posttranslationalmodificationsof pages 1-3)

Blockquote: This blockquote summarizes the core regulatory logic of CDK5, including its non-cyclin activators, normal membrane targeting, pathological p25/p29 generation, and key post-translational modifications. It is useful for quickly explaining how CDK5 shifts from physiological neuronal signaling to disease-associated hyperactivation.

Activation Mechanism and Regulation

The activation and spatial regulation of CDK5 is tightly controlled through several mechanisms. Under physiological conditions, p35 and p39 undergo N-terminal myristoylation at Gly2, which targets these regulatory subunits to membrane fractions and recruits CDK5 to the cell membrane (pao2021threedecadesof pages 1-3, pao2021threedecadesof pages 3-4). Active CDK5/p35 complexes can also be present in the cytoplasm, with localization modulated by CDK5-mediated phosphorylation of p35 at Ser8, which releases p35 from the membrane and promotes cytoplasmic localization (nikhil2023cdk5anoncogene pages 1-2).

Under pathological conditions involving elevated intracellular calcium, the protease calpain cleaves p35 to generate p25 and p39 to generate p29 (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 1-2, tian2022focusingoncyclindependent pages 3-4, allnutt2020physiologicalandpathological pages 1-2). These truncated activators lack the N-terminal myristoylation signal and ubiquitination sequence, resulting in significantly longer protein half-lives and loss of membrane targeting (nikhil2023cdk5anoncogene pages 1-2, allnutt2020physiologicalandpathological pages 1-2). The resulting CDK5/p25 or CDK5/p29 complexes become hyperactive and mislocalize to the cytoplasm and nucleus, where they phosphorylate aberrant substrates and contribute to neurotoxicity (nikhil2023cdk5anoncogene pages 1-2, tian2022focusingoncyclindependent pages 3-4, allnutt2020physiologicalandpathological pages 1-2, pao2021threedecadesof pages 4-5).

CDK5 activity is further modulated by post-translational modifications. Phosphorylation at Thr14 inhibits kinase activity, while phosphorylation at Tyr15 is generally stimulatory but context-dependent (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 3-4). Phosphorylation at Ser159 in the T-loop is critical for p35 binding and activation (pao2021threedecadesof pages 3-4). S-nitrosylation at Cys83 within the ATP-binding pocket suppresses CDK5 activity, and acetylation at Lys33 impairs ATP binding, thereby reducing catalytic activity (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 3-4, gao2021posttranslationalmodificationsof pages 1-3).

Substrate Repertoire

CDK5 phosphorylates an extensive array of substrates involved in diverse cellular processes. The following table summarizes major substrates with their specific phosphorylation sites and functional consequences:

Table: This table summarizes major CDK5 substrates across synaptic, cytoskeletal, mitochondrial, circadian, mTOR, and disease-related pathways, with phosphorylation sites and functional consequences. It is useful for quickly mapping CDK5’s direct molecular outputs to specific cellular processes.

Recent studies have identified novel CDK5 substrates. In 2024, a study demonstrated that CDK5 can form a complex with cyclin B1 and regulate mitotic fidelity, expanding beyond its traditional non-cell-cycle roles (zheng2024cdk5cyclinb1regulates pages 1-4). In 2023, CDK5 was shown to phosphorylate PRMT1 at Ser307 in response to amino acids, promoting PRMT1 translocation from nucleus to cytoplasm and lysosome, which in turn methylates WDR24 to activate the mTORC1 pathway (yin2023cdk5prmt1wdr24signalingcascade pages 1-3). Additionally, CDK5-mediated hyperphosphorylation of Tau at Thr217 was demonstrated in 2025 to impair neuronal synaptic structure and exacerbate cognitive impairment in Alzheimer's disease models (fu2025cdk5mediatedhyperphosphorylationof pages 1-2).

Subcellular Localization

CDK5 exhibits dynamic subcellular localization that is critical for determining its functional outcomes. Under normal physiological conditions, active CDK5/p35 and CDK5/p39 complexes are primarily localized to cell membranes due to myristoylation of p35/p39, with additional cytoplasmic pools regulated by phosphorylation-dependent release mechanisms (nikhil2023cdk5anoncogene pages 1-2, pao2021threedecadesof pages 1-3, pao2021threedecadesof pages 3-4, gao2021posttranslationalmodificationsof pages 1-3).

During pathological conditions, calpain-mediated cleavage of p35/p39 to p25/p29 removes the myristoylation signal, allowing CDK5 complexes to translocate to the nucleus (nikhil2023cdk5anoncogene pages 1-2, allnutt2020physiologicalandpathological pages 1-2, gao2021posttranslationalmodificationsof pages 1-3). Nuclear localization of CDK5/p25 is strongly associated with neurotoxicity in neurodegenerative diseases such as Alzheimer's and Parkinson's disease (allnutt2020physiologicalandpathological pages 1-2, pao2021threedecadesof pages 4-5). However, nuclear CDK5 can also function as a tumor suppressor in gastric cancer, where it exhibits unique nuclear localization and accesses substrates that promote anti-oncogenic signaling (nikhil2023cdk5anoncogene pages 1-2, nishimura2025thedualityof pages 1-2).

CDK5 also regulates the subcellular localization of its substrates. For example, CDK5 phosphorylates SIRT2 at Ser331 and Ser335, promoting its translocation from cytoplasm to nucleus and subsequent dopaminergic neuronal death in Parkinson's disease models (yan2022cdk5phosphorylationinducedsirt2 pages 1-2). Similarly, CDK5 phosphorylates HSP90AA1 at Ser595 under basal conditions, inhibiting HSP90AA1 and disrupting TFEB nuclear localization and autophagy induction (gao2021posttranslationalmodificationsof pages 1-3).

Signaling and Biochemical Pathways

CDK5 functions as a central hub kinase that integrates multiple signaling networks in neurons and other cell types. The following sections detail the major pathways in which CDK5 participates.

Synaptic Function and Plasticity

CDK5 plays essential roles in synaptic transmission and plasticity. At presynaptic terminals, CDK5 phosphorylates Munc18 at Ser158, promoting dissociation from Syntaxin 1A and facilitating synaptic vesicle fusion and neurotransmitter release (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5). CDK5 regulates endocytosis through phosphorylation of Dynamin I (Ser774, Ser778) and Amphiphysin I (Ser272, Ser276, Ser285), thereby controlling synaptic vesicle recycling (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5). Additionally, CDK5 modulates Ca²⁺ influx by phosphorylating voltage-dependent calcium channels including L-VDCC (Ser783) and CaV2.2 (Ser2013), which increases neurotransmitter release probability (pao2021threedecadesof pages 4-5).

At postsynaptic sites, CDK5 phosphorylates the NMDA receptor subunit NR2A at Ser1232, enhancing NMDA receptor function and contributing to synaptic plasticity (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5). CDK5-mediated phosphorylation of PSD-95 at Thr19, Ser25, and Ser35 regulates synaptic plasticity by reducing co-clustering with ion channels and promoting scaffold protein degradation (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5). For synaptic homeostasis, CDK5 phosphorylates SPAR at Ser1328, priming it for Plk2-mediated phosphorylation and ubiquitin-dependent degradation, thereby promoting synaptic weakening (pao2021threedecadesof pages 4-5).

Neuronal Migration and Cytoskeletal Regulation

During brain development, CDK5 orchestrates neuronal migration through phosphorylation of multiple cytoskeletal regulators. CDK5 phosphorylates doublecortin (Dcx) at Ser710, NUDEL at Ser198/Thr219/Ser231, and FAK at Ser732, all of which regulate microtubule organization and neuronal migration (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5). Recent work demonstrated that CDK5 phosphorylates RapGEF2 at Ser1124, subsequently activating Rap1, a key factor modulating neuronal migration (pao2021threedecadesof pages 3-4). CDK5 also phosphorylates PAK1 at Thr212 and Map1b to regulate neurite outgrowth and axonal formation (pao2021threedecadesof pages 3-4, pao2021threedecadesof pages 4-5).

mTORC1 Signaling Pathway

A recent discovery revealed a novel CDK5-PRMT1-WDR24 signaling cascade that promotes mTORC1 activation. In response to amino acids, CDK5 phosphorylates protein arginine methyltransferase 1 (PRMT1) at Ser307, promoting PRMT1 translocation from nucleus to cytoplasm and lysosomes (yin2023cdk5prmt1wdr24signalingcascade pages 1-3). This relocalized PRMT1 then methylates WDR24, an essential component of the GATOR2 complex, which in turn activates the mTORC1 pathway to regulate cell growth, metabolism, and tumor progression (yin2023cdk5prmt1wdr24signalingcascade pages 1-3).

Mitochondrial Dynamics and Function

CDK5 regulates mitochondrial dynamics by phosphorylating dynamin-related protein 1 (Drp1) at Ser616, which promotes GTPase activity and accelerates mitochondrial fission (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 4-5). This mechanism is implicated in dopaminergic neuronal loss in Parkinson's disease models and in regulating cancer cell survival programs (nikhil2023cdk5anoncogene pages 3-6, tian2022focusingoncyclindependent pages 3-4). CDK5 also phosphorylates Parkin at Ser131, reducing its E3 ubiquitin ligase activity and impairing mitochondrial quality control (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 4-5). Additionally, CDK5 phosphorylates peroxidases Prx1 (Thr90) and Prx2 (Thr89), decreasing their peroxidase activity and increasing reactive oxygen species production (tian2022focusingoncyclindependent pages 3-4, pao2021threedecadesof pages 4-5).

Tau Phosphorylation and Neurodegeneration

CDK5 is a major tau kinase that phosphorylates tau at multiple sites including Thr181, Ser202, Thr205, Thr217, Ser235, Ser396, and Ser404 (pao2021threedecadesof pages 4-5, fu2025cdk5mediatedhyperphosphorylationof pages 1-2). Hyperphosphorylation of tau reduces its microtubule-binding capacity and promotes tau aggregation, contributing to neurofibrillary tangle formation in Alzheimer's disease (pao2021threedecadesof pages 4-5). A 2025 study specifically demonstrated that CDK5-mediated hyperphosphorylation of Tau at Thr217 impairs neuronal synaptic structure, reduces levels of synaptic proteins Drebrin and PSD95, and exacerbates cognitive impairment in Alzheimer's disease models (fu2025cdk5mediatedhyperphosphorylationof pages 1-2).

Circadian Clock Regulation

CDK5 regulates circadian rhythms by phosphorylating core clock proteins. CDK5 phosphorylates CLOCK at Thr451 and Thr461, promoting CLOCK nuclear translocation and enhancing its circadian transcriptional activity (pao2021threedecadesof pages 4-5). Additionally, CDK5 phosphorylates PER2 at Ser394, stabilizing PER2 and promoting its nuclear translocation to regulate circadian gene expression (pao2021threedecadesof pages 4-5).

Additional Signaling Pathways

CDK5 participates in DNA damage response by phosphorylating ATM at Ser794 (pao2021threedecadesof pages 4-5), regulates APP processing by phosphorylating APP at Thr668 (pao2021threedecadesof pages 4-5), and modulates autophagy through multiple mechanisms including EndoB1 phosphorylation (tian2022focusingoncyclindependent pages 3-4). CDK5 also interfaces with MAPK and PI3K/Akt signaling pathways in various pathological contexts (tian2022focusingoncyclindependent pages 3-4, requejoaguilar2023cdk5andaberrant pages 1-2).

Recent Developments and Latest Research (2023-2025)

Recent research has expanded our understanding of CDK5 in both physiological and pathological contexts:

1. Novel Mitotic Function (2024): A groundbreaking study published in Nature demonstrated that CDK5 can form a complex with cyclin B1 and regulate mitotic fidelity, challenging the traditional view that CDK5 has no cell cycle function (zheng2024cdk5cyclinb1regulates pages 1-4).

2. mTORC1 Regulation (2023): The discovery of the CDK5-PRMT1-WDR24 signaling cascade revealed a new mechanism by which CDK5 senses amino acids and activates mTORC1, with implications for cancer therapy (yin2023cdk5prmt1wdr24signalingcascade pages 1-3).

3. Tau Thr217 Phosphorylation (2025): Detailed mechanistic studies confirmed CDK5 as the kinase responsible for tau phosphorylation at Thr217, a site now recognized as a critical biomarker for Alzheimer's disease, and demonstrated that this phosphorylation directly impairs synaptic structure (fu2025cdk5mediatedhyperphosphorylationof pages 1-2).

4. Context-Dependent Oncogenic/Tumor Suppressor Roles (2023): A comprehensive review established that CDK5's role as oncogene or tumor suppressor depends primarily on its subcellular localization, with nuclear CDK5 acting as a tumor suppressor in gastric cancer but cytoplasmic CDK5 promoting oncogenesis in most other cancers (nikhil2023cdk5anoncogene pages 1-2).

5. Synaptic Remodeling in Stroke (2026): A salidroside derivative (SHPL-49) was shown to enhance synaptic remodeling in stroke models by modulating the CDK5/p35/p25 pathway, representing a potential therapeutic approach for ischemic stroke (zheng2024cdk5cyclinb1regulates pages 1-4).

Current Applications and Clinical Relevance

CDK5 has emerged as a promising therapeutic target for multiple diseases. In Alzheimer's disease, specific CDK5/p25 inhibitors such as the peptide TFP5 have shown neuroprotective effects by preventing aberrant tau phosphorylation and neuronal death in preclinical models (tian2022focusingoncyclindependent pages 3-4, allnutt2020physiologicalandpathological pages 1-2). A 2023 study demonstrated that a Cdk5-derived peptide inhibitor can specifically disrupt Cdk5/p25 interaction and ameliorate neurodegenerative phenotypes in cell and mouse models (allnutt2020physiologicalandpathological pages 1-2).

In cancer, the context-dependent role of CDK5 presents both challenges and opportunities. While CDK5 inhibition may be beneficial for most cancers where CDK5 acts as an oncogene, the unique tumor-suppressive role of nuclear CDK5 in gastric cancer suggests that targeting CDK5 substrates individually or in combination with CDK5 modulation could create valuable clinical opportunities (nikhil2023cdk5anoncogene pages 1-2).

CDK5 inhibition has also shown promise in Parkinson's disease models, where preventing Cdk5-mediated SIRT2 nuclear translocation or Drp1-dependent mitochondrial fission protected dopaminergic neurons (tian2022focusingoncyclindependent pages 3-4, yan2022cdk5phosphorylationinducedsirt2 pages 1-2).

Expert Analysis and Future Perspectives

CDK5 functions as a molecular rheostat where different activity levels and subcellular localizations elicit distinct functional outcomes (nikhil2023cdk5anoncogene pages 1-2). The discovery that hyperactivation through p25 formation results in apoptosis suggests a counterintuitive therapeutic strategy of "dialing up" CDK5 activity rather than inhibiting it to selectively kill cancer cells (nikhil2023cdk5anoncogene pages 1-2).

The dual role of CDK5 as both a neurodevelopmental regulator and a pathological mediator underscores the complexity of targeting this kinase therapeutically. Recent structural and mechanistic insights have enabled development of more selective inhibitors that distinguish between CDK5/p35 and CDK5/p25 complexes, potentially allowing therapeutic intervention in pathological states while preserving physiological functions (allnutt2020physiologicalandpathological pages 1-2).

Emerging evidence suggests that post-translational modifications of CDK5, including phosphorylation, S-nitrosylation, sumoylation, and acetylation, serve as molecular switches controlling kinase activity and could represent alternative therapeutic intervention points (gao2021posttranslationalmodificationsof pages 1-3). Targeting these regulatory mechanisms rather than directly inhibiting catalytic activity may offer improved specificity and reduced side effects.

The recognition that CDK5's functional output is defined by its substrates suggests that combination therapies targeting both CDK5 and specific downstream substrates may prove more effective than CDK5 inhibition alone (nikhil2023cdk5anoncogene pages 1-2, pao2021threedecadesof pages 4-5).

Conclusions

CDK5 is a multifunctional proline-directed serine/threonine kinase that plays essential roles in neuronal development, synaptic function, and cellular metabolism while contributing to multiple pathological processes when dysregulated. Its unique activation mechanism via p35/p39 rather than cyclins, dynamic subcellular localization, and extensive substrate repertoire make CDK5 a critical hub kinase integrating diverse signaling networks. Recent advances have revealed novel functions in mitotic regulation, mTORC1 activation, and precise mechanisms of tau phosphorylation, expanding therapeutic opportunities across neurodegenerative diseases and cancer. The context-dependent nature of CDK5 function emphasizes the need for nuanced therapeutic strategies that consider subcellular localization, activation state, and substrate specificity.

References

1. (nikhil2023cdk5anoncogene pages 1-2): Kumar Nikhil and Kavita Shah. Cdk5: an oncogene or an anti-oncogene: location location location. Molecular Cancer, Nov 2023. URL: https://doi.org/10.1186/s12943-023-01895-8, doi:10.1186/s12943-023-01895-8. This article has 21 citations and is from a highest quality peer-reviewed journal.

2. (tian2022focusingoncyclindependent pages 1-2): Zhen Tian, Bin Feng, Xing-Qin Wang, and Jiao Tian. Focusing on cyclin-dependent kinases 5: a potential target for neurological disorders. Frontiers in Molecular Neuroscience, Nov 2022. URL: https://doi.org/10.3389/fnmol.2022.1030639, doi:10.3389/fnmol.2022.1030639. This article has 23 citations.

3. (pao2021threedecadesof pages 1-3): Ping-Chieh Pao and Li-Huei Tsai. Three decades of cdk5. Journal of Biomedical Science, Nov 2021. URL: https://doi.org/10.1186/s12929-021-00774-y, doi:10.1186/s12929-021-00774-y. This article has 172 citations and is from a domain leading peer-reviewed journal.

4. (allnutt2020physiologicalandpathological pages 1-2): Annamarie B. Allnutt, Ariana K. Waters, Santosh Kesari, and Venkata Mahidhar Yenugonda. Physiological and pathological roles of cdk5: potential directions for therapeutic targeting in neurodegenerative disease. ACS chemical neuroscience, 11:1218-1230, Apr 2020. URL: https://doi.org/10.1021/acschemneuro.0c00096, doi:10.1021/acschemneuro.0c00096. This article has 95 citations and is from a peer-reviewed journal.

5. (gao2021posttranslationalmodificationsof pages 1-3): Gui-Bin Gao, Yue Sun, Run-Dong Fang, Ying Wang, Yang Wang, and Qing-Yu He. Post-translational modifications of cdk5 and their biological roles in cancer. Molecular Biomedicine, Jul 2021. URL: https://doi.org/10.1186/s43556-021-00029-0, doi:10.1186/s43556-021-00029-0. This article has 17 citations and is from a peer-reviewed journal.

6. (pao2021threedecadesof pages 3-4): Ping-Chieh Pao and Li-Huei Tsai. Three decades of cdk5. Journal of Biomedical Science, Nov 2021. URL: https://doi.org/10.1186/s12929-021-00774-y, doi:10.1186/s12929-021-00774-y. This article has 172 citations and is from a domain leading peer-reviewed journal.

7. (tian2022focusingoncyclindependent pages 3-4): Zhen Tian, Bin Feng, Xing-Qin Wang, and Jiao Tian. Focusing on cyclin-dependent kinases 5: a potential target for neurological disorders. Frontiers in Molecular Neuroscience, Nov 2022. URL: https://doi.org/10.3389/fnmol.2022.1030639, doi:10.3389/fnmol.2022.1030639. This article has 23 citations.

8. (pao2021threedecadesof pages 4-5): Ping-Chieh Pao and Li-Huei Tsai. Three decades of cdk5. Journal of Biomedical Science, Nov 2021. URL: https://doi.org/10.1186/s12929-021-00774-y, doi:10.1186/s12929-021-00774-y. This article has 172 citations and is from a domain leading peer-reviewed journal.

9. (nikhil2023cdk5anoncogene pages 3-6): Kumar Nikhil and Kavita Shah. Cdk5: an oncogene or an anti-oncogene: location location location. Molecular Cancer, Nov 2023. URL: https://doi.org/10.1186/s12943-023-01895-8, doi:10.1186/s12943-023-01895-8. This article has 21 citations and is from a highest quality peer-reviewed journal.

10. (fu2025cdk5mediatedhyperphosphorylationof pages 1-2): Kangyue Fu, Nan Lin, Yiwen Xu, En Huang, Raoli He, Zhixin Wu, Dianbo Qu, Xiaochun Chen, and Tianwen Huang. Cdk5-mediated hyperphosphorylation of tau217 impairs neuronal synaptic structure and exacerbates cognitive impairment in alzheimer’s disease. Translational Psychiatry, Aug 2025. URL: https://doi.org/10.1038/s41398-025-03551-9, doi:10.1038/s41398-025-03551-9. This article has 8 citations and is from a peer-reviewed journal.

11. (yin2023cdk5prmt1wdr24signalingcascade pages 1-3): Shasha Yin, Liu Liu, Lauren E. Ball, Yalong Wang, Mark T. Bedford, Stephen A. Duncan, Haizhen Wang, and Wenjian Gan. Cdk5-prmt1-wdr24 signaling cascade promotes mtorc1 signaling and tumor growth. Cell Reports, 42:112316, Apr 2023. URL: https://doi.org/10.1016/j.celrep.2023.112316, doi:10.1016/j.celrep.2023.112316. This article has 32 citations and is from a highest quality peer-reviewed journal.

12. (yan2022cdk5phosphorylationinducedsirt2 pages 1-2): Jianguo Yan, Pei Zhang, Jie Tan, Mao Li, Xingfeng Xu, Xiaoyun Shao, Fang Fang, Zhenyou Zou, Yali Zhou, and B. Tian. Cdk5 phosphorylation-induced sirt2 nuclear translocation promotes the death of dopaminergic neurons in parkinson’s disease. npj Parkinson's Disease, Apr 2022. URL: https://doi.org/10.1038/s41531-022-00311-0, doi:10.1038/s41531-022-00311-0. This article has 31 citations and is from a domain leading peer-reviewed journal.

13. (zheng2024cdk5cyclinb1regulates pages 1-4): Xiao-Feng Zheng, Aniruddha Sarkar, Humphrey Lotana, Aleem Syed, Huy Nguyen, Richard G. Ivey, Jacob J. Kennedy, Jeffrey R. Whiteaker, Bartłomiej Tomasik, Kaimeng Huang, Feng Li, Alan D. D’Andrea, Amanda G. Paulovich, Kavita Shah, Alexander Spektor, and Dipanjan Chowdhury. Cdk5-cyclin b1 regulates mitotic fidelity. Nature, 633:932-940, Sep 2024. URL: https://doi.org/10.1038/s41586-024-07888-x, doi:10.1038/s41586-024-07888-x. This article has 23 citations and is from a highest quality peer-reviewed journal.

14. (nishimura2025thedualityof pages 1-2): Yoshiaki V. Nishimura and Takeshi Kawauchi. The duality of cdk5: a master regulator in neurodevelopment and a hijacked oncogene in cancer. Cells, 14:1876, Nov 2025. URL: https://doi.org/10.3390/cells14231876, doi:10.3390/cells14231876. This article has 2 citations.

15. (requejoaguilar2023cdk5andaberrant pages 1-2): Raquel Requejo-Aguilar. Cdk5 and aberrant cell cycle activation at the core of neurodegeneration. Jan 2023. URL: https://doi.org/10.4103/1673-5374.360165, doi:10.4103/1673-5374.360165. This article has 45 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01

Citations

1. pao2021threedecadesof pages 1-3
2. pao2021threedecadesof pages 3-4
3. pao2021threedecadesof pages 4-5
4. gao2021posttranslationalmodificationsof pages 1-3
5. tian2022focusingoncyclindependent pages 3-4
6. allnutt2020physiologicalandpathological pages 1-2
7. tian2022focusingoncyclindependent pages 1-2
8. nishimura2025thedualityof pages 1-2
9. https://doi.org/10.1186/s12943-023-01895-8,
10. https://doi.org/10.3389/fnmol.2022.1030639,
11. https://doi.org/10.1186/s12929-021-00774-y,
12. https://doi.org/10.1021/acschemneuro.0c00096,
13. https://doi.org/10.1186/s43556-021-00029-0,
14. https://doi.org/10.1038/s41398-025-03551-9,
15. https://doi.org/10.1016/j.celrep.2023.112316,
16. https://doi.org/10.1038/s41531-022-00311-0,
17. https://doi.org/10.1038/s41586-024-07888-x,
18. https://doi.org/10.3390/cells14231876,
19. https://doi.org/10.4103/1673-5374.360165,